- Home
- CSTL vs MYD Comparison
CSTL vs MYD Comparison
Compare CSTL & MYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- MYD
- Stock Information
- Founded
- CSTL 2007
- MYD 1991
- Country
- CSTL United States
- MYD United States
- Employees
- CSTL N/A
- MYD N/A
- Industry
- CSTL Medical Specialities
- MYD Investment Bankers/Brokers/Service
- Sector
- CSTL Health Care
- MYD Finance
- Exchange
- CSTL Nasdaq
- MYD Nasdaq
- Market Cap
- CSTL 456.2M
- MYD 456.4M
- IPO Year
- CSTL 2019
- MYD N/A
- Fundamental
- Price
- CSTL $19.46
- MYD $10.01
- Analyst Decision
- CSTL Strong Buy
- MYD
- Analyst Count
- CSTL 6
- MYD 0
- Target Price
- CSTL $37.67
- MYD N/A
- AVG Volume (30 Days)
- CSTL 462.3K
- MYD 253.1K
- Earning Date
- CSTL 08-04-2025
- MYD 01-01-0001
- Dividend Yield
- CSTL N/A
- MYD 4.55%
- EPS Growth
- CSTL N/A
- MYD N/A
- EPS
- CSTL N/A
- MYD N/A
- Revenue
- CSTL $347,083,000.00
- MYD N/A
- Revenue This Year
- CSTL N/A
- MYD N/A
- Revenue Next Year
- CSTL $1.36
- MYD N/A
- P/E Ratio
- CSTL N/A
- MYD N/A
- Revenue Growth
- CSTL 38.43
- MYD N/A
- 52 Week Low
- CSTL $15.45
- MYD $8.76
- 52 Week High
- CSTL $35.84
- MYD $11.30
- Technical
- Relative Strength Index (RSI)
- CSTL 55.41
- MYD 48.21
- Support Level
- CSTL $18.18
- MYD $9.96
- Resistance Level
- CSTL $20.63
- MYD $10.08
- Average True Range (ATR)
- CSTL 0.77
- MYD 0.07
- MACD
- CSTL 0.07
- MYD 0.02
- Stochastic Oscillator
- CSTL 57.36
- MYD 47.62
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.